Clinical Trials Browser

Burkitt Lymphoma, Leukemia

NCT03774082 2025-12-11

REACH 5

Phase 2 Completed

46 enrolled 21 charts

Lymphoid

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease, Lymphoma, Follicular

NCT04669210 2025-07-04

PTCyRuxo

Phase 2 Completed

128 enrolled

LymphoidOther hematologic neoplasm

Graft vs Host Disease, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01375140 2025-06-08

Ruxolitinib and Lenalidomide for Patients With Myelofibrosis

Phase 2 Completed

31 enrolled 8 charts

Myeloid

Polycythemia Vera, Primary Myelofibrosis

NCT04281498 2025-02-04

Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation

Phase 2 Completed

6 enrolled 11 charts

Myeloid

Primary Myelofibrosis

NCT01594216 2024-06-12

Ruxolitinib in Estrogen Receptor Positive Breast Cancer

Phase 2 Completed

25 enrolled 8 charts

Breast

Estrogen-receptor Positive Invasive Metastatic Breast Cancer

NCT04055844 2023-11-07

Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS

Phase 2 Completed

14 enrolled 20 charts

MyeloidOther hematologic neoplasm

Leukemia, Monocytic, Acute, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT01712308 2023-10-10

Sotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or Anemia

Phase 2 Completed

56 enrolled 9 charts

Classical hematologyMyeloid

Anemia, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

NCT03144687 2022-06-16

A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis

Phase 2 Completed

23 enrolled 31 charts

Myeloid

Myeloproliferative Disorders, Primary Myelofibrosis

NCT01981850 2022-01-05

A Phase 2 Study of RO7490677 In Participants With Myelofibrosis

Phase 2 Completed

125 enrolled 38 charts

Myeloid

Fibrosis, Polycythemia Vera, Primary Myelofibrosis

NCT02953678 2021-11-24

A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)

Phase 2 Completed

71 enrolled 24 charts 1 FDA

Graft vs Host Disease

NCT02092324 2020-11-16

Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia

Phase 2 Completed

51 enrolled 25 charts

Other hematologic neoplasm

Leukemia, Neutrophilic, Chronic, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

NCT01369498 2020-07-01

Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis

Phase 2 Completed

54 enrolled 16 charts

MyeloidOther hematologic neoplasm

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Primary Myelofibrosis

NCT01348490 2020-01-28

Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF)

Phase 2 Completed

66 enrolled 18 charts

Myeloid

Myeloproliferative Disorders

NCT02267278 2019-06-12

Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (MF)

Phase 2 Completed

25 enrolled 8 charts

Myeloid

Polycythemia Vera, Primary Myelofibrosis

NCT02142036 2019-03-13

MetAction

Phase 2 Completed

50 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT01965119 2018-11-01

JAK2

Phase 2 Completed

20 enrolled

Lymphoid

Hodgkin Disease, Recurrence

NCT01877005 2018-08-22

HIJAK

Phase 2 Completed

33 enrolled

Lymphoid

Hodgkin Disease

NCT00639002 2018-02-13

A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma

Phase 2 Completed

13 enrolled 7 charts

Plasma cell

Multiple Myeloma

NCT01340651 2014-03-10

Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients

Phase 2 Completed

41 enrolled 15 charts

Myeloid

Myeloproliferative Disorders, Primary Myelofibrosis

Clinical Trials

A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia

REACH 5

PTCyRuxo

Ruxolitinib and Lenalidomide for Patients With Myelofibrosis

Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation

Ruxolitinib in Estrogen Receptor Positive Breast Cancer

Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS

Sotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or Anemia

A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis

A Phase 2 Study of RO7490677 In Participants With Myelofibrosis

A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)

Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia

Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis

Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF)

Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (MF)

MetAction

JAK2

HIJAK

A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma

Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients